Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies."
Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies in the oncology and immunology arenas.
How do these collaborators and competitors compare for investors? Here's how Pfizer and Bristol-Myers Squibb (BMS) stack up against each other.
Source: Fool.com
Pfizer Inc. Stock
€26.49
1.050%
The stock is one of the favorites of our community with 30 Buy predictions and 4 Sell predictions.
As a result the target price of 40 € shows a very positive potential of 51.0% compared to the current price of 26.49 € for Pfizer Inc..
